News coverage about TESARO (NASDAQ:TSRO) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. TESARO earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.9262791480503 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- TESARO Receives Positive CHMP Opinion for ZEJULA® – GlobeNewswire (press release) (globenewswire.com)
- RBC Capital Begins Coverage on TESARO, Inc. (TSRO) With An Initial Rating Of “Sector Perform” – First News 24 (firstnewspaper24.com)
- $118.02 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter (americanbankingnews.com)
- 2017 United States Dog Nourishing Cream Market Shows Speedy Growth. (reports.pr-inside.com)
- TESARO : Receives Positive CHMP Opinion for ZEJULA® (4-traders.com)
TSRO has been the topic of a number of research analyst reports. Cann reissued a “buy” rating and issued a $199.00 price target on shares of TESARO in a research note on Monday, June 5th. Citigroup Inc. restated a “buy” rating and issued a $216.00 price objective on shares of TESARO in a report on Monday, September 11th. Robert W. Baird restated a “neutral” rating and issued a $140.00 price objective (down previously from $155.00) on shares of TESARO in a report on Thursday, August 10th. Cowen and Company decreased their price objective on TESARO from $145.00 to $124.00 and set a “market perform” rating on the stock in a report on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 price objective on TESARO and gave the company a “buy” rating in a report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO presently has a consensus rating of “Buy” and an average target price of $171.42.
TESARO (NASDAQ TSRO) traded up 1.67% during trading on Friday, reaching $117.16. The company’s stock had a trading volume of 1,253,722 shares. The company’s market capitalization is $6.35 billion. The company’s 50-day moving average is $121.74 and its 200-day moving average is $140.42. TESARO has a 1-year low of $96.52 and a 1-year high of $192.94.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. During the same period in the prior year, the firm posted ($1.28) EPS. TESARO’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities analysts anticipate that TESARO will post ($8.67) EPS for the current year.
In related news, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Insiders have sold 25,100 shares of company stock worth $3,387,465 over the last 90 days. Corporate insiders own 40.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://ledgergazette.com/2017/09/17/tesaro-tsro-given-news-sentiment-score-of-0-21.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.